BridgeBio to Unveil Long-Term Outcomes of Acoramidis Study at AHA 2024

BridgeBio Pharma, Inc. BBIO, a prominent commercial-stage biopharmaceutical company headquartered in Palo Alto, California, has announced an impending presentation at the 2024 American Heart Association (AHA) Scientific Sessions. This presentation will highlight the extended outcomes from the ATTRibute-CM Phase 3 study, regarding the efficacy of Acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM), a debilitating genetic disease. The data to be presented will encapsulate a 42-month period from their open-label extension study, showcasing the long-term effects and outcomes for patients under Acoramidis treatment.

Understanding ATTR-CM and the Impact of Acoramidis

ATTR-CM is a progressive and often fatal heart condition caused by the accumulation of misfolded transthyretin protein within the heart tissue. Acoramidis, developed by BBIO, is designed to stabilize the transthyretin protein and prevent its aggregation, thereby aiming to improve patient outcomes and quality of life. The forthcoming presentation will offer valuable insights into the drug's sustained efficacy and safety over an extended period, which is crucial for patients suffering from this chronic condition.

Significance of the 42-Month Outcomes Data

The comprehensive data from the 42 months of treatment with Acoramidis provides not only a testament to the drug’s potential but also reinforces BridgeBio’s commitment to addressing the challenges of genetic diseases. Investors and healthcare professionals alike anticipate the detailed outcomes to further illuminate Acoramidis’s role in managing ATTR-CM, influencing both clinical practice and market dynamics for BBIO's portfolio.

BridgeBio, Acoramidis, ATTR-CM